Consideration of the Cranio Facial Difficulty Index
2002-01-01 Segu', M; Contini, E; Segu', S
Valutazione dell’infiltrazione marginale in prodotti per restauri estetici
2004-01-01 Vitale, Mc; Piacentini, C; Chiesa, M; Baruto, A; Segu', M
Valutazione dell'efficacia degli apparecchi di avanzamento mandibolare nella terapia dell'apnea ostruttiva del sonno
2016-01-01 Santagostini, A; Segu', M; Fadani, G; Fanfulla, F; Collesano, V
L’impatto del dolore orofacciale sulla qualita’ della vita: studio caso-controllo
2003-01-01 Canale, C; Lobbia, S; Segu', M; Piacentini, C; Collesano, V
Differenza fra sessi nella prevalenza dei disordni temporomandibolari secondo i RDC/tmd
2007-01-01 Chiappe, G; Monterotti, I; Romagnoli, M; Segu', M; Bosco, M
Sleep and temporomandibular disorders: a case-control study
2003-01-01 Segu', M; Collesano, V; Manni, R; Masseroli, C
Oral appliance treatment for obstructive sleep apnoea in a patient with severe dental condition: case report
2015-01-01 Santagostini, A; Segu', M; Manni, R; Collesano, V
Survival and response to therapy in 139 patients with advanced renal cell carcinoma treated with low-dose IL-2 and IFN alpha: Influence of the prognostic risk at the time of diagnosis
2006-01-01 Vaglio, A; Bongiovanni, C; Alberici, F; Manna, C; Passalacqua, R; Buti, S; David, S; Buzio, C
Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP)
2017-01-01 De Giorgi, U; Scagliarini, S; Basso, U; Galli, L; Mosillo, C; Caserta, C; Rossetti, S; Guida, A; Bearz, A; Buti, S; Lo Re, G; Valcamonico, F; Hamzaj, A; Cognetti, F; Rastelli, F; Fornarini, G; Porta, C; Del Bene, G; Turci, D; Procopio, G
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2007-01-01 Longarini, R; Buti, S; Bosio, G; Brighenti, M; Porzio, R; Negri, F; Passalacqua, R
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors
2017-01-01 Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials
2011-01-01 Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crinò, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, E on bealf of GOIRC and NVALT groups
Renal metastases to pancreas: do not operate all and always?
2014-01-01 Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S
The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study
2017-01-01 Vitale, Mg; Masini, C; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report
2014-01-01 Altavilla, A; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Hamzaj, A; Marrocolo, F; De Angelis, V; Bracarda, S
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study
2007-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
2015-01-01 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Maintenance biotherapy for metastatic renal cancer with IL-2 and IFN-alpha: A Phase III, randomized, multicentre trial
2004-01-01 Passalacqua, R; Buzio, C; Labianca, R; Porta, C; Dalla Chiesa, M; Buti, S; Tomasello, G; Camisa, R; Frassoldati, A; Caminiti, C
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab
2017-01-01 Tiseo, M; Veneziani, M; Gelsomino, F; Facchinetti, F; Bordi, P; Rapacchi, E; Squadrilli, A; Buti, S; Missale, G; Ardizzoni, A
Erythrocyte mean corpuscolar volume change during pemetrexed chemotherapy in advanced non small cell lung cancer patients
2012-01-01 Bordi, P; Buti, S; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, S; Pilotto, S; Camisa, R; Ardizzoni, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Consideration of the Cranio Facial Difficulty Index | 1-gen-2002 | Segu', M; Contini, E; Segu', S | |
| Valutazione dell’infiltrazione marginale in prodotti per restauri estetici | 1-gen-2004 | Vitale, Mc; Piacentini, C; Chiesa, M; Baruto, A; Segu', M | |
| Valutazione dell'efficacia degli apparecchi di avanzamento mandibolare nella terapia dell'apnea ostruttiva del sonno | 1-gen-2016 | Santagostini, A; Segu', M; Fadani, G; Fanfulla, F; Collesano, V | |
| L’impatto del dolore orofacciale sulla qualita’ della vita: studio caso-controllo | 1-gen-2003 | Canale, C; Lobbia, S; Segu', M; Piacentini, C; Collesano, V | |
| Differenza fra sessi nella prevalenza dei disordni temporomandibolari secondo i RDC/tmd | 1-gen-2007 | Chiappe, G; Monterotti, I; Romagnoli, M; Segu', M; Bosco, M | |
| Sleep and temporomandibular disorders: a case-control study | 1-gen-2003 | Segu', M; Collesano, V; Manni, R; Masseroli, C | |
| Oral appliance treatment for obstructive sleep apnoea in a patient with severe dental condition: case report | 1-gen-2015 | Santagostini, A; Segu', M; Manni, R; Collesano, V | |
| Survival and response to therapy in 139 patients with advanced renal cell carcinoma treated with low-dose IL-2 and IFN alpha: Influence of the prognostic risk at the time of diagnosis | 1-gen-2006 | Vaglio, A; Bongiovanni, C; Alberici, F; Manna, C; Passalacqua, R; Buti, S; David, S; Buzio, C | |
| Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP) | 1-gen-2017 | De Giorgi, U; Scagliarini, S; Basso, U; Galli, L; Mosillo, C; Caserta, C; Rossetti, S; Guida, A; Bearz, A; Buti, S; Lo Re, G; Valcamonico, F; Hamzaj, A; Cognetti, F; Rastelli, F; Fornarini, G; Porta, C; Del Bene, G; Turci, D; Procopio, G | |
| Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC) | 1-gen-2007 | Longarini, R; Buti, S; Bosio, G; Brighenti, M; Porzio, R; Negri, F; Passalacqua, R | |
| Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors | 1-gen-2017 | Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S | |
| Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials | 1-gen-2011 | Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crinò, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, E on bealf of GOIRC and NVALT groups | |
| Renal metastases to pancreas: do not operate all and always? | 1-gen-2014 | Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S | |
| The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study | 1-gen-2017 | Vitale, Mg; Masini, C; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C | |
| Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report | 1-gen-2014 | Altavilla, A; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Hamzaj, A; Marrocolo, F; De Angelis, V; Bracarda, S | |
| Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study | 1-gen-2007 | Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R | |
| Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) | 1-gen-2015 | Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G | |
| Maintenance biotherapy for metastatic renal cancer with IL-2 and IFN-alpha: A Phase III, randomized, multicentre trial | 1-gen-2004 | Passalacqua, R; Buzio, C; Labianca, R; Porta, C; Dalla Chiesa, M; Buti, S; Tomasello, G; Camisa, R; Frassoldati, A; Caminiti, C | |
| Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab | 1-gen-2017 | Tiseo, M; Veneziani, M; Gelsomino, F; Facchinetti, F; Bordi, P; Rapacchi, E; Squadrilli, A; Buti, S; Missale, G; Ardizzoni, A | |
| Erythrocyte mean corpuscolar volume change during pemetrexed chemotherapy in advanced non small cell lung cancer patients | 1-gen-2012 | Bordi, P; Buti, S; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, S; Pilotto, S; Camisa, R; Ardizzoni, A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista1767
Data di pubblicazione
- 2020 - 2025192
- 2010 - 2019832
- 2000 - 2009517
- 1990 - 1999174
- 1980 - 198951
- 1979 - 19791
Editore
- ELSEVIER25
- SAGE PUBLICATIONS LTD17
- DIKE GIURIDICA15
- Elsevier13
- ASCO pubs11
- ELSEVIER IRELAND LTD7
- ASCO6
- ELSEVIER SCIENCE INC5
- SAGE5
- SPRINGERNATURE4
Rivista
- DIGESTIVE AND LIVER DISEASE101
- GASTROENTEROLOGY100
- ANNALS OF ONCOLOGY93
- BLOOD89
- JOURNAL OF CLINICAL ONCOLOGY58
- HAEMATOLOGICA56
- NEUROLOGICAL SCIENCES47
- UNITED EUROPEAN GASTROENTEROLOGY ...46
- ANNALS OF THE RHEUMATIC DISEASES36
- REUMATISMO26
Keyword
- Helicobacter pylori10
- sclerosi sistemica6
- Bioengineering5
- Gastroenterology5
- HCV5
- UV5
- GERD4
- Lungs4
- anodal stimulation3
- beat-to-beat variability of cardi...3
Lingua
- eng926
- ita177
- fre1
Accesso al fulltext
- no fulltext1735
- reserved26
- open6